Dynavax Technologies Corporation (NASDAQ:DVAX) dropped 5% during mid-day trading on Tuesday . The company traded as low as $20.60 and last traded at $21.18. Approximately 1,863,115 shares changed hands during trading, a decline of 34% from the average daily volume of 2,831,640 shares. The stock had previously closed at $22.30.

DVAX has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Monday, July 10th. Royal Bank Of Canada set a $7.00 price target on shares of Dynavax Technologies Corporation and gave the company a “hold” rating in a research note on Wednesday, July 26th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Cowen and Company reaffirmed an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and upped their price target for the company from $6.00 to $27.00 in a research note on Monday, July 31st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $25.00.

The firm’s market cap is $1.16 billion. The stock’s 50 day moving average price is $20.82 and its 200-day moving average price is $11.90.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. During the same quarter in the previous year, the company posted ($0.75) EPS. On average, analysts forecast that Dynavax Technologies Corporation will post ($1.63) EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in DVAX. Teachers Advisors LLC boosted its stake in Dynavax Technologies Corporation by 9.1% during the 4th quarter. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 5,618 shares during the last quarter. Nationwide Fund Advisors boosted its stake in Dynavax Technologies Corporation by 11.2% during the 1st quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 2,786 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Dynavax Technologies Corporation by 61.7% during the 1st quarter. Russell Investments Group Ltd. now owns 125,059 shares of the biopharmaceutical company’s stock worth $744,000 after purchasing an additional 47,735 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Dynavax Technologies Corporation by 30.0% during the 1st quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 9,634 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Dynavax Technologies Corporation by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 176,996 shares of the biopharmaceutical company’s stock worth $1,053,000 after purchasing an additional 6,623 shares during the last quarter. 60.20% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-stock-price-down-5/1637233.html.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.